What is SpyBiotech?
SpyBiotech is a biotechnology company based in Oxford, UK, established in 2017. The company is focused on pioneering a novel vaccine platform technology designed to address a broad spectrum of health challenges, including infectious diseases, various forms of cancer, and chronic conditions. Its innovative approach aims to create more effective and versatile vaccines, positioning it as a key player in the biopharmaceutical sector.
How much funding has SpyBiotech raised?
SpyBiotech has raised a total of $37.5M across 2 funding rounds:
Angel/Seed
$5M
Series A
$32.5M
Angel/Seed (2017): $5M with participation from GV and Oxford Sciences Innovation
Series A (2021): $32.5M led by Braavos Investment Advisers, GV, Future Fund, and Oxford Sciences Innovation
Key Investors in SpyBiotech
GV
GV is a venture capital firm founded in 2001 that invests across multiple stages and sectors, focusing on enterprise solutions, life sciences, consumer products, and frontier technology innovations. GV operates globally, providing financial backing to promising startups and growth-stage businesses.
Oxford Sciences Innovation
Oxford Science Enterprises is an independent investment company created in 2015 to found, fund and build transformational businesses via its unique partnership with the University of Oxford, the world's #1 research university.
Future Fund
Future Fund was established in 2006 to invest for the benefit of future generations of Australians, helping to ease growing pressure on government finances. Future Fund is headquartered in Australia.
What's next for SpyBiotech?
With the recent major strategic investment, SpyBiotech is poised for an accelerated growth phase. The company is likely to expand its research and development capabilities, potentially initiating new clinical trials and further refining its vaccine platform. This significant backing suggests a strong investor confidence in SpyBiotech's technology and its potential to disrupt multiple therapeutic areas. The company's focus on infectious diseases, cancer, and chronic diseases indicates a strategic market approach, aiming for broad impact and commercial viability.
See full SpyBiotech company page
